LOUISVILLE, Kentucky, May 8, 2026, 04:07 EDT
- Humana lowered its 2026 GAAP EPS view to not less than $8.36. The company, though, stuck with its adjusted profit target of at least $9.00.
- Some recent market reports are raising doubts that the stock’s rebound toward $247 is outpacing the company’s actual earnings recovery plan.
- Medicare Advantage pricing, benefits, and quality ratings come up next, and Humana’s exposure here tops that of most big competitors.
Humana’s stock comeback is hitting a snag. The insurer has cut its 2026 earnings forecast under U.S. accounting standards, yet investors keep betting on a Medicare Advantage turnaround that remains out of reach.
Humana, headquartered in Louisville, lowered its 2026 full-year GAAP diluted EPS outlook to a minimum of $8.36, down from its previous floor of $8.89, while sticking to at least $9.00 for adjusted EPS — which strips out certain items. First-quarter revenue climbed to $39.65 billion compared to $32.11 billion last year. Adjusted EPS, though, slipped to $10.31, from $11.58.
The stock debate has grown more pointed lately. According to News.Az, pulling data from Simply Wall St, Humana shares jumped over 25% in the past month, changing hands near $247—well above a fair-value mark pegged at $213. AsatuNews, echoing that sentiment, called it a valuation test following the company’s guidance cut, referencing a price-to-earnings multiple of 26.3 and the same $247.12 trading level.
Humana last changed hands at $247.12, putting its market capitalization around $29.7 billion and leaving the price-to-earnings ratio close to 26.4, market data show. The stock showed minimal movement in the most recent after-hours quote.
The focus right now is Medicare Advantage—the private alternative to traditional Medicare serving seniors and some Americans with disabilities. Humana stands out here: about 80% of its revenue ties back to this segment, Reuters has noted, while CVS Health’s Aetna pulls in 33% and UnitedHealth’s UnitedHealthcare just 12%.
Humana posted a first-quarter insurance benefit ratio of 89.4%, inching past its target of just under 90%. That figure tracks what portion of premiums go toward medical costs—lower numbers typically help margins. Still, the company is sticking with its full-year prediction of a 92.75% benefit ratio, give or take 25 basis points, flagging that rising care expenses and government reimbursement remain front and center.
Chief Executive Jim Rechtin described the quarter as a “solid start to the year,” highlighting advances in quality, customer experience, and care. In its prepared statement, Humana noted that medical and pharmacy cost trends came in a bit better than anticipated early in the year. Still, the company cautioned that it continues to project a gap between 2027 Medicare Advantage rates and ongoing medical cost trends. policy.humana.com
The government’s last word on 2027 Medicare Advantage rates offered a boost for the sector, though pressure remains. Centers for Medicare & Medicaid Services expects final policies to drive up payments to Medicare Advantage plans by 2.48%—that’s an increase of over $13 billion for 2027. Factor in risk-score trends, and the payment jump comes to 4.98%.
Managed-care names got a boost last month following the rate decision. Shares of UnitedHealth, Humana, CVS, and Elevance all climbed after the news broke. Mizuho’s Ann Hynes told Reuters this should allow the industry to widen margins in 2027—assuming benefit cuts go through. Leerink’s Whit Mayo expects the group to become “more investable,” at the very least. Reuters
The trickier question is the impact of those benefit reductions. According to Reuters, investors and industry insiders are bracing for Medicare Advantage plans to pare back perks like dental, vision, hearing, gym access, meal delivery, and transportation support next year. “Humana will be cutting back the most,” Bahl & Gaynor COO Kevin Gade told Reuters. Reuters
Humana’s capital actions appear cautious rather than bold. According to a filing, the company bought back 564,400 shares during the first quarter, paying an average of $182.13 apiece. As of April 28, $2.72 billion remained available for repurchases. That leaves management flexibility, though it points to buybacks not being the primary lever for the earnings reset.
The risk is straightforward. Should new Medicare Advantage enrollees end up costing more than projected, or if Humana can’t claw back higher “Star” ratings, or if benefit trims drive people elsewhere, margin gains may not materialize. The company noted that its 2026 adjusted EPS forecast already bakes in a year-on-year drop, blaming the drag from Star Ratings—a one-to-five scale that determines bonus payments from Medicare. SEC
Investors are left juggling both sides here: Humana’s first quarter didn’t undercut the recovery plan, but it also lacked the punch to end the valuation debate. Coming up, the focus shifts to 2027 bids, benefit design details, and what second-quarter cost trends reveal — numbers that rarely grab headlines, yet they’ll determine if the rally still has fuel or if it’s outpaced the fundamentals.
